Skip to search formSkip to main contentSkip to account menu

vaniprevir

National Institutes of Health

Related topics

Related topics

1 relation
MK-7009

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Phase Separation Macrocyclization in a Complex Pharmaceutical Setting: Application toward the Synthesis of Vaniprevir.
A phase separation/continuous flow strategy employing an oxidative Glaser-Hay coupling of alkynes has been applied toward the… 
2017
2017
Single‐Dose and Multiple‐Dose Pharmacokinetics of Vaniprevir in Healthy Men
Vaniprevir is an inhibitor of the hepatitis C virus (HCV) NS3/4A protease. The aim of these double‐blind, placebo‐controlled… 
2017
2017
Features of the Second Wave of the First Generation Protease Inhibitors: Effect and Tolerance
Simeprevir, asunaprevir, vaniprevir, paritaprevir, and other direct-acting antivirals (DAAs) developed after the first-generation… 
2016
2016
Vaniprevir plus peginterferon alfa‐2b and ribavirin in treatment‐experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies
Vaniprevir is a macrocyclic hepatitis C virus (HCV) non‐structural (NS)3/4A protease inhibitor. The objective of these phase 3… 
2016
2016
Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir and BMS-788329 combination therapy in human hepatocyte chimeric mice.
2015
2015
Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study
AbstractBackgroundVaniprevir is a potent macrocyclic hepatitis C virus (HCV) nonstructural protein 3/4A protease inhibitor. This… 
2015
2015
Liver-to-Plasma Vaniprevir (MK-7009) Concentration Ratios in HCV-Infected Patients
Background Some drugs that are actively taken up into the liver exhibit greater than dose proportional increases in plasma… 
2014
2014
A case of successful treatment with telaprevir-based triple therapy for hepatitis C infection after treatment failure with vaniprevir-based triple therapy.
2012
2012
Pharmacokinetic / Pharmacodynamic Predictors of Clinical Potency for 1 Hepatitis C Non-Nucleoside Polymerase and Protease Inhibitors 2 3
1 Hepatitis C Non-Nucleoside Polymerase and Protease Inhibitors 2 3 Authors: Micaela B. Reddy, Peter N. Morcos, Sophie Le Pogam… 
Review
2011
Review
2011
Emerging therapeutic options in hepatitis C virus infection.
The current standard of care for patients with chronic hepatitis C virus (HCV) infection is pegylated interferon alfa in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)